Early Access — free while we kick the tires
EdgarHawk

Malamut Richard

Director

Director
1 filing analyzed · 1 company · Latest 2024-09-16

Companies

Company Buys Sells Direction
Chromocell Therapeutics Corp PTHS 1 0 Net buying

Activity

September 2024
medium
Buy
10,400 shares
$9,825
Significance 4/10

Director Malamut buys 10,400 shares at $0.94 amid stock down -82.3% from 52-week high of $48.00

Director Richard Malamut purchased 10,400 shares at $0.94 on 2024-09-12, adding to holdings that now stand at 91,565 shares post-transaction. The purchase occurs at a price far removed from the stock's 52-week high of $48.00 — the current price of $8.50 is -82.3% below that peak, suggesting a sustained period of significant stock deterioration. The company reported full-year net income of $-1,771,619.00, indicating persistent unprofitability, which contextualizes the downward price movement as driven by fundamental weakness rather than temporary sentiment. The transaction represents a modest position increase of 10,400 shares against existing holdings, noteworthy chiefly because it occurs in an environment of deep underperformance and negative earnings, where the economic rationale for accumulation is not immediately apparent.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access